Accelerating Innovation in the Creation of Biovalue: The Cell and Gene Therapy Catapult

Research output: Contribution to journalArticlepeer-review


The field of regenerative medicine (RM) has considerable therapeutic promise that is proving difficult to realize. As a result, governments have supported the establishment of intermediary agencies to “accelerate” innovation. This paper examines in detail one such agency, the UK's Cell and Gene Therapy Catapult (CGTC). We describe CGTC’s role as an accelerator agency and its value-narrative, which combines both “health and wealth.” Drawing on the notion of socio-technical imaginaries, we unpack the tensions within this narrative and its instantiation as the CGTC cell therapy infrastructure is built and engages with other agencies, some of which have different priorities and roles to play within the RM field.
Original languageEnglish
JournalScience, Technology and Human Values
Early online date6 Apr 2017
Publication statusPublished - 6 Apr 2017

Cite this